CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer

Human Immunology

Volumn 74, Issue 8, 2013, Pages 1003-1008

  Zambra, Francis Maria Báo ^a   Biolchi, Vanderlei ^a   Brum, Ilma Simoni ^a   Chies, José Artur Bogo ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; DNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE VOLUME;

BENIGN PROSTATIC HYPERPLASIA; BPH; CCL; CCR; CHEMOKINE (C-C MOTIF) LIGAND; CHEMOKINE (C-C MOTIF) RECEPTOR; PCA; PROSTATE CANCER; PROSTATE-SPECIFIC ANTIGEN; PSA;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ODDS RATIO; POLYMORPHISM, GENETIC; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, CCR2; RECEPTORS, CCR5;

EID: 84879883658     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.04.031     Document Type: Article

References (50)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C.D., Parkin D. GLOBOCAN 2008. Cancer incidence and mortality worldwide: IARC CancerBase No. 10. 2012, International Agency for Research on Cancer, Lyon, France, [Online] http://globocan.iarc.fr (30 August 2012, date last accessed).
2. Instituto Nacional de Câncer (INCA), (09 February 2012, date last accessed). http://www.inca.gov.br/estimativa/2012.
3. De Nunzio C., Kramer G., Marberger M., Montironi R., Nelson W., Schröder F., et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011, 60:106-117.
4. Kirby R.S. The natural history of benign prostatic hyperplasia what have we learned in the last decade. Urology 2000, 56(Suppl. 1):3-6.
5. Sciarra A., Di Silverio F., Salciccia S., Autran Gomez A.M., Gentilucci A., Gentile V. Inflammation and chronic prostatic diseases: evidence for a link?. Eur Urol 2007, 52:964-972.
6. Alcaraz A., Hammerer P., Tubaro A., Schröder F.H., Castro R. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol 2009, 55:864-875.
7. Vindrieux D., Escobar P., Lazennec G. Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer 2009, 16:663-673.
8. Fujita K., Ewing C.M., Getzenberg R.H., Parsons J.K., Isaacs W.B., Pavlovich C.P. Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia. Prostate 2010, 70(5):473-481.
9. Ruffini P.A., Morandi P., Cabioglu N., Altundag K., Cristofanilli M. Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer 2007, 109(12):2392-2404.
10. Mañes S., Mira E., Colomer R., Montero S., Real L.M., Gómez-Moutón C., et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 2003, 198:1381-1389.
11. Murphy P.M., Baggiolini M., Charo I.F., Hebert C.A., Horuk R., Matsushima K., et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Ver 2000, 52(1):145-176.
12. Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006, 354(6):610-621.
13. Lu Y., Cai Z., Galson D.L., Xiao G., Liu Y., George D.E., et al. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 2006, 66(12):1311-1318.
14. Lu Y., Cai Z., Xiao G., Liu Y., Keller E.T., Yao Z., et al. CCR2 expression correlates with prostate cancer progression. J Cell Biochem 2007, 101(3):676-685.
15. Zhang J., Lu Y., Pienta K.J. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst 2010, 102(8):522-528.
16. Yu Y.P., Landsittel D., Jing L., Nelson J., Ren B., Liu L., et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004, 22:2790-2799.
17. Smith M.W., Carrington M., Winkler C., Lomb D., Dean M., Huttley G., et al. CCR2 chemokine receptor and AIDS progression. Nat Med 1997, 3:1052-1053.
18. Yeh C.B., Tsai H.T., Chen Y.C., Kuo W.H., Chen T.Y., Hsieh Y.H., et al. Genetic polymorphism of CCR2-64I increased the susceptibility of hepatocellular carcinoma. J Surg Oncol 2010, 102(3):264-270.
19. Narter K.F., Agachan B., Sozen S., Cincin Z.B., Isbir T. CCR2-64I is a risk factor for development of bladder cancer. Genet Mol Res 2010, 9(2):685-692.
20. Zafiropoulos A., Crikas N., Passam A.M., Spandidos D.A. Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet 2004, 41(5):e59.
21. Balistreri C.R., Caruso C., Grimaldi M.P., Listì F., Vasto S., Orlando V., et al. CCR5 receptor: biologic and genetic implications in age-related diseases. Ann NY Acad Sci 2007, 1100:162-172.
22. König J.E., Senge T., Allhoff E.P., Konig W. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 2004, 58(2):121-129.
23. Vaday G.G., Peehl D.M., Kadam P.A., Lawrence D.M. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006, 66:124-134.
24. Magnani M., Castro-Gomez R.H., Aoki M.N., Gregório E.P., Libos F., Morimoto H.K., et al. Analysis of peripheral T cells and the CC chemokine receptor (CCR5) delta32 polymorphism in prostate cancer patients treated with carboxymethyl-glucan (CM-G). Nat Prod Res 2011, [Epub ahead of print]. 10.1080/14786419.2010.535159.
25. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86(3):367-377.
26. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382(6593):722-725.
27. Dean M., Carrington M., Winkler C., Huttley G.A., Smith M.W., Allikmets R., et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996, 273(5283):1856-1862.
28. Srivastava A., Pandey S.N., Choudhuri G., Mittal B. CCR5D32 polymorphism: associated with gallbladder cancer susceptibility. Scand J Immunol 2008, 67:516-522.
29. Balistreri C.R., Carruba G., Calabrò M., Campisi I., Di Carlo D., Lio D., et al. CCR5 proinflammatory allele in prostate cancer risk: a pilot study in patients and centenarians from Sicily. Ann NY Acad Sci 2009, 1155:289-292.
30. Josefowicz S.Z., Rudensky A. Control of regulatory T cell lineage commitment and maintenance. Immunity 2009, 30:616-625.
31. Kang S.G., Piniecki R.J., Hogenesch H., Lim H.W., Wiebke E., Braun S.E., et al. Identification of a chemokine network that recruits FoxP3(+) regulatory T cells into chronically inflamed intestine. Gastroenterology 2007, 132:966-981.
32. Tan M.C., Goedegebuure P.S., Belt B.A., Flaherty B., Sankpal N., Gillanders W.E., et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 2009, 182:1746-1755.
33. Hembruff S.L., Cheng N. Chemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targeting. Cancer Ther 2009, 7:254-267.
34. Osorio R.G. O sistema classificatório de ''cor ou raça'' do IBGE 2003, Instituto de Pesquisa Econômica Aplicada, Brasília, 50 p.
35. Santos N.P., Ribeiro-Rodrigues E.M., Ribeiro-Dos-Santos A.K., Pereira R., Gusmão L., Amorim A., et al. Assessing individual interethnic admixture and population substructure using a 48-insertion-deletion (INSEL) ancestry informative marker (AIM) panel. Hum Mutat 2010, 31(2):184-190. 10.1002/humu.21159.
36. Pena S.D., Di Pietro G., Fuchshuber-Moraes M., Genro J.P., Hutz M.H., Kehdy Fde S., et al. The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS One 2011, 6(2):e17063. 10.1371/journal.pone.0017063.
37. Biolchi V., Neto B.S., Koff W., Brum I.S. Androgen receptor CAG polymorphism and the risk of benign prostatic hyperplasia in a Brazilian population. Int Braz J Urol 2012, 38:372-378.
38. Neto B.S., Koff W.J., Biolchi V., Brenner C., Biolo K.D., Spritzer P.M., et al. Polymorphic CAG and GGC repeat lengths in the androgen receptor gene and prostate cancer risk: analysis of a Brazilian population. Cancer Invest 2008, 26(1):74-80.
39. Vargas A.E., da Silva M.A., Silla L., Chies J.A. Polymorphisms of chemokine receptors and eNOS in Brazilian patients with sickle cell disease. Tissue Antigens 2005, 66(6):683-690.
40. Chies J.A., Hutz M.H. Hight frequency of the CCR5-delta32 variant among individuals from an admixed Brazilian population with sickle cell anemia. Braz J Med Biol Res 2003, 36:71-75.
41. De Marzo A.M., Platz E.A., Sutcliffe S., Xu J., Grönberg H., Drake C.G., et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007, 7(4):256-269.
42. Tang J., Yang J. Etiopathogenesis of benign prostatic hypeprlasia. Indian J Urol 2009, 25(3):312-317.
43. Attar R., Agachan B., Kuran S.B., Cacina C., Sozen S., Yurdum L.M., et al. Association of CCL2 and CCR2 gene variants with endometrial cancer in Turkish women. In Vivo 2010, 24:2243-2248.
44. Petersen D.C., Severi G., Hoang H.N., Padilla E.J.D., Southey M.C., English D.R., et al. No association between common chemokine and chemokine receptor gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2008, 17(12):3615-3617.
45. Iyer R.K., Kim P.S., Bando J.M., Lu K.V., Gregg J.P., Grody W.W. A multiethnic study of Delta32ccr5 and ccr2b-V64I allele distribution in four Los Angeles populations. Diagn Mol Pathol 2001, 10(2):105-110.
46. Acosta A.X., Sampaio R.G., Spínola J.L., Galvão-Castro B. Distribution of the CCR2-64I allele in three Brazilian ethnic groups. Genet Mol Biol 2003, 26:3. São Paulo. 10.1590/S1415-47572003000300004.
47. Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, survival in human breast cancer. Clin Cancer Res 2000, 6:3282-3289.
48. Degerli N., Yilmaz E., Bardakci F. The D32 allele distribution of the CCR5 gene and its relationship with certain cancers in a Turkish population. Clin Biochem 2005, 38:248-252.
49. Vargas A.E., Cechim G., Correa J.F., Gomes P.A., Macedo Gde S., de Medeiros R.M., et al. Pros and cons of a missing chemokine receptor-comments on "Is the European spatial distribution of the HIV-1-resistant CCR5-D32 allele formed by a breakdown of the pathocenosis due to the historical Roman expansion?" by Eric Faure and Manuela Royer-Carenzi (2008). Infect Genet Evol 2009, 9(4):387-389.
50. Rodríguez-Rodríguez L., González-Juanatey C., García-Bermúdez M., Vázquez-Rodríguez T.R., Miranda-Filloy J.A., Fernández-Gutiérrez B., et al. CCR5δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study. Arthritis Res Ther 2011, 13(4):R133. 10.1186/ar3444.